This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Jim Cramer: Themes That Are Dying in 2014

Then there's biotech. Here's a group that had been dominated by Amgen (AMGN), Celgene (CELG), Biogen Idec (BIIB), Gilead (GILD) and Regeneron (REGN). You can throw in names like BioMarin (BMRN) or Vertex (VRTX)  or Pharmacyclics (PCYC). This was the most important leadership group in the market. It was brought on by, one, a number of big drug approvals and, two, some super-mergers that seemed to be happening pretty much once a month.

While the approvals are still occurring, the biggest one -- that of Gilead's hepatitis C pill -- so far seems below forecast, and that's crimping the whole group. Given the size of the patient population, and the life-saving nature of the pill, I do not know why sales haven't been better. Each week they seem to get worse, which is, I believe the proximate cause for the whole group's decline, as they are all linked via powerful ETFs. As they've gone down, no safety net of mergers and acquisitions has appeared to save the group.

At the same time, the sheer number of new biotech stocks has been overwhelming. Plus, many left-for-dead biotechs, which had been the equivalent of penny stocks, have had new life breathed into them. I wish I could say it was justified. But it's usually just another sign of rank speculation. Let's not forget that the group always, always, always underperforms when a pronounced economic growth spurt is in the air, and that's just what people think we are having now.

So aerospace, cloud and biotech all have issues that cannot be solved quickly. The first might turn when we get earnings reports. The second and third, though, can only stop declining if the IPO window closes and the economy falters -- and, in the case of biotech, we'd need to see a pick-up in Gilead's new drug sales and a new wave of M&A to take advantage of the decline in prices.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long CELG.

Editor's Note: This article was originally published at 6:45 a.m. EST on Real Money on March 31.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Our Tweets

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs